FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2281084277> ?p ?o ?g. }

• W2281084277 abstract "Abstract Introduction Recent studies demonstrating the effectiveness of eculizumab in the treatment of atypical hemolytic uremic syndrome (aHUS) have increased the need for more rapid and objective diagnostic tests to help confirm the diagnosis of aHUS over other thrombotic microangiopathies (TMA). Methods We performed a retrospective study of all patients enrolled in the Ohio State University TTP/aHUS Registry since 2003. From this cohort of patients diagnosed with an acute TMA (platelets<100 x 109/ with schistocytes present, and without an alternative explanation), patients with a pretreatment serum creatinine >2.25 mg/dL and measureable ADAMTS13 activity (>10%) were analyzed. The clinical and demographic data for these 19 patients are shown in Table 1. Banked plasma samples from these study subjects were used to measure complement activation factors Bb (alternative pathway (AP)), C4d (classical pathway), C3a, (generalized complement activation), C5a, and C5b-9 complex (terminal complement pathway (TCP)). These complement biomarker data were analyzed in the context of a documented mutation in complement regulatory proteins and response to therapy with PEX and/or eculizumab. Response was defined as a normal platelet count and improved serum creatinine (at 6 months) independent of PEX therapy or with continued eculizumab therapy. Results The median complement biomarker data at presentation are shown in Table 2. Complement activation products are generally sensitive biomarkers for aHUS patients. Notably, elevation of the AP (Bb) and the TCP (C5b-9) biomarkers were more prominent and were seen in 16/19 and 19/19 patients respectively. This is in contrast to previously published data from acquired TTP patients from our group that demonstrated less pronounced activation of the AP and TCP at presentation (accepted for publication, JTH). Similar levels of alternative, classical and terminal complement activation were seen among patients regardless of mutation status or response to PEX. In a preliminary analysis using a one sample T-test model, (Bb) activation was shown to be significantly lower in the non-responder to eculizumab compared to the 8 responding patients. TCP activation was also lower in the non-responder but did not show statistical significance. Conclusions Complement biomarkers of the alternative and terminal complement pathway may more precisely define the diagnosis of aHUS. These hypothesis generating data suggest that pre-treatment complement biomarkers provide valuable information in the diagnosis of aHUS and could be useful in the prediction of response to eculizumab Disclosures: No relevant conflicts of interest to declare." @default.
• W2281084277 created "2016-06-24" @default.
• W2281084277 creator A5012869295 @default.
• W2281084277 creator A5040063597 @default.
• W2281084277 creator A5053638396 @default.
• W2281084277 creator A5082516137 @default.
• W2281084277 date "2013-11-15" @default.
• W2281084277 modified "2023-09-27" @default.
• W2281084277 title "Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS" @default.
• W2281084277 doi "https://doi.org/10.1182/blood.v122.21.3552.3552" @default.
• W2281084277 hasPublicationYear "2013" @default.
• W2281084277 type Work @default.
• W2281084277 sameAs 2281084277 @default.
• W2281084277 citedByCount "0" @default.
• W2281084277 crossrefType "journal-article" @default.
• W2281084277 hasAuthorship W2281084277A5012869295 @default.
• W2281084277 hasAuthorship W2281084277A5040063597 @default.
• W2281084277 hasAuthorship W2281084277A5053638396 @default.
• W2281084277 hasAuthorship W2281084277A5082516137 @default.
• W2281084277 hasConcept C111684460 @default.
• W2281084277 hasConcept C126322002 @default.
• W2281084277 hasConcept C143998085 @default.
• W2281084277 hasConcept C151730666 @default.
• W2281084277 hasConcept C159654299 @default.
• W2281084277 hasConcept C189446657 @default.
• W2281084277 hasConcept C203014093 @default.
• W2281084277 hasConcept C2777637130 @default.
• W2281084277 hasConcept C2777878052 @default.
• W2281084277 hasConcept C2777991916 @default.
• W2281084277 hasConcept C2779134260 @default.
• W2281084277 hasConcept C2779343474 @default.
• W2281084277 hasConcept C2780306776 @default.
• W2281084277 hasConcept C2781197716 @default.
• W2281084277 hasConcept C55493867 @default.
• W2281084277 hasConcept C71318922 @default.
• W2281084277 hasConcept C71924100 @default.
• W2281084277 hasConcept C86803240 @default.
• W2281084277 hasConcept C90924648 @default.
• W2281084277 hasConceptScore W2281084277C111684460 @default.
• W2281084277 hasConceptScore W2281084277C126322002 @default.
• W2281084277 hasConceptScore W2281084277C143998085 @default.
• W2281084277 hasConceptScore W2281084277C151730666 @default.
• W2281084277 hasConceptScore W2281084277C159654299 @default.
• W2281084277 hasConceptScore W2281084277C189446657 @default.
• W2281084277 hasConceptScore W2281084277C203014093 @default.
• W2281084277 hasConceptScore W2281084277C2777637130 @default.
• W2281084277 hasConceptScore W2281084277C2777878052 @default.
• W2281084277 hasConceptScore W2281084277C2777991916 @default.
• W2281084277 hasConceptScore W2281084277C2779134260 @default.
• W2281084277 hasConceptScore W2281084277C2779343474 @default.
• W2281084277 hasConceptScore W2281084277C2780306776 @default.
• W2281084277 hasConceptScore W2281084277C2781197716 @default.
• W2281084277 hasConceptScore W2281084277C55493867 @default.
• W2281084277 hasConceptScore W2281084277C71318922 @default.
• W2281084277 hasConceptScore W2281084277C71924100 @default.
• W2281084277 hasConceptScore W2281084277C86803240 @default.
• W2281084277 hasConceptScore W2281084277C90924648 @default.
• W2281084277 hasLocation W22810842771 @default.
• W2281084277 hasOpenAccess W2281084277 @default.
• W2281084277 hasPrimaryLocation W22810842771 @default.
• W2281084277 hasRelatedWork W1566551321 @default.
• W2281084277 hasRelatedWork W1984003625 @default.
• W2281084277 hasRelatedWork W1990765087 @default.
• W2281084277 hasRelatedWork W2040948402 @default.
• W2281084277 hasRelatedWork W2110998634 @default.
• W2281084277 hasRelatedWork W2142258354 @default.
• W2281084277 hasRelatedWork W2324849902 @default.
• W2281084277 hasRelatedWork W2327539391 @default.
• W2281084277 hasRelatedWork W2342628844 @default.
• W2281084277 hasRelatedWork W2346370975 @default.
• W2281084277 hasRelatedWork W2505085952 @default.
• W2281084277 hasRelatedWork W2725015469 @default.
• W2281084277 hasRelatedWork W3036413078 @default.
• W2281084277 hasRelatedWork W3045184294 @default.
• W2281084277 hasRelatedWork W3092541694 @default.
• W2281084277 hasRelatedWork W3128953896 @default.
• W2281084277 hasRelatedWork W3160153707 @default.
• W2281084277 hasRelatedWork W3173251004 @default.
• W2281084277 hasRelatedWork W3200275131 @default.
• W2281084277 hasRelatedWork W3211567380 @default.
• W2281084277 isParatext "false" @default.
• W2281084277 isRetracted "false" @default.
• W2281084277 magId "2281084277" @default.
• W2281084277 workType "article" @default.